




# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP  
600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701-3271  
WWW.FULBRIGHT.COM

MARK B. WILSON  
PARTNER  
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3035  
TELEPHONE: (512) 474-5201  
FACSIMILE: (512) 536-4598

October 30, 2003

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
October 30, 2003	
Date	Mark B. Wilson

**MS DD**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/632,539 entitled "COMPARATIVE ANALYSIS OF NUCLEIC ACIDS USING POPULATION TAGGING" – Matthew M. Winkler and David Brown*  
*Our reference: AMBI:063US*


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references A1-A4, B1-B8 and C1-C11.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/AMBI:063US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

  
Mark B. Wilson  
Reg. No. 37,259

MBW/kmv  
Encl.: as noted  
25350275.1



**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Matthew M. Winkler

David Brown

Serial No.: 10/632,539

Filed: July 31, 2003

For: COMPARATIVE ANALYSIS OF  
NUCLEIC ACIDS USING POPULATION  
TAGGING

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: AMBI:063US

**CERTIFICATE OF MAILING**  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.

October 30, 2003

Date

  
Mark E. Wilson

**INFORMATION DISCLOSURE STATEMENT**

**MS DD**

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/AMBI:063US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,




Mark B. Wilson  
Reg. No. 37,259  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: October 30, 2003

Form PTO-1449 (modified)



Atty. Docket No.

Serial No.

AMBI:063US

10/632,539

List of Patents and Publications for Applicant

Applicant

Matthew M. Winkler and David Brown

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

July 31, 2003

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,262,311	11/16/93	Pardee <i>et al.</i>	435	91.2	03/11/92
	A2	5,545,522	08/13/96	Van Gelder <i>et al.</i>	435	6	10/05/92
	A3	5,861,245	01/19/99	McClelland	435	6	06/06/95
	A4	6,132,997	10/17/200	Shannon	435	91.21	05/28/99

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	EP 0 416 817	03/13/91	Europe			
	B2	EP 0 870 842	10/14/98	Eurpoe			
	B3	WO 00/05409	02/03/00	PCT			
	B4	WO 00/24939	05/04/00	PCT			
	B5	WO 00/75356	12/14/00	PCT			
	B6	WO 02/064835	01/31/02	PCT			
	B7	WO 97/27317	07/31/97	PCT			
	B8	WO 98/08973	03/05/98	PCT			

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Kato, "Adaptor-tagged competitive PCR: a novel method for measuring relative gene expression," <i>Nucleic Acids Research</i> , Oxford University Press, Surrey, GB, 25(22):4694-4696, 1997.
	C2	Kita <i>et al.</i> , "Modulation of polygulutamine-induced cell death by genes identified by expression profiling," <i>Human Molecular Genetics</i> , 11(19):2279-2287, 2002.

25340833.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

AMBI:063US

Serial No.

10/632,539

Applicant

Matthew M. Winkler and David Brown

Filing Date:

July 31, 2003

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C3	Matoba <i>et al.</i> , "Gene expression in mouse cerebellum during its development," <i>Gene</i> , 241:125-131, 2000.
	C4	Matoba <i>et al.</i> , "Gene expression profiling of mouse postnatal cerebellar development," <i>Physiol. Genomics</i> , 4:155-164, 2000.
	C5	Phillips <i>et al.</i> , "Antisense RNA amplification: A linear amplification method for analyzing the mRNA population," <i>Methods, a Companion to Methods in Enzymology</i> , 10(3):283-288, 1996.
	C6	Sakai <i>et al.</i> , "Microarray hybridization with fractionated cDNA: enhanced identification of differentially expressed genes," <i>Analytical Biochemistry</i> , 287(1):32-37, 2000.
	C7	Shuldiner <i>et al.</i> , "RNA template-specific polymerase chain reaction RS-PCR a novel strategy to reduce dramatically false positives," <i>Gene</i> , 91(1):139-142, 1990.
	C8	Welch <i>et al.</i> , "Fingerprinting genomes using PCR with arbitrary primers," <i>Nucleic Acids Research</i> , Oxford University Press, Surrey, GB, 18(24):7213-7218, 1990.
	C9	Welch <i>et al.</i> , "Nucleic acid fingerprinting by PCR-based methods: applications to problems in aging and mutagenesis," <i>Mutation Research</i> , 338(1-6):215-229, 1995.
	C10	Wytenbach <i>et al.</i> , "Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease," <i>Human Molecular Genetics</i> , 10(17):1829-1845, 2001.
	C11	Zimmerman <i>et al.</i> , "Technical aspects of quantitative competitive PCR," <i>Biotechniques</i> , 21(2):268-270, 1996.

25340833.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.